NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $44.83 +2.13 (+4.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$42.46▼$45.1350-Day Range$30.32▼$45.9552-Week Range$12.20▼$53.00Volume185,716 shsAverage Volume123,928 shsMarket Capitalization$581.89 millionP/E RatioN/ADividend YieldN/APrice Target$51.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Neurogene alerts: Email Address Neurogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside14.5% Upside$51.33 Price TargetShort InterestBearish12.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.15) to ($4.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.16 out of 5 starsMedical Sector801st out of 936 stocksPharmaceutical Preparations Industry373rd out of 436 stocks 3.6 Analyst's Opinion Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurogene's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.37% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 34.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NGNE. Previous Next 2.4 News and Social Media Coverage News SentimentNeurogene has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neurogene this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for NGNE on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added Neurogene to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.92% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.15) to ($4.07) per share.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Neurogene Stock (NASDAQ:NGNE)Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Read More NGNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGNE Stock News HeadlinesJuly 18, 2024 | americanbankingnews.comNeurogene Inc. (NASDAQ:NGNE) Receives $51.33 Consensus PT from AnalystsJune 18, 2024 | businesswire.comNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 5, 2024 | businesswire.comNeurogene to Participate in Upcoming ConferencesMay 14, 2024 | markets.businessinsider.comNeurogene’s Strong Pipeline and Financial Health Prompt Buy RatingMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene Amid Positive Outlook on NGN-401 and EXACT TechnologyMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)May 10, 2024 | investorplace.comNGNE Stock Earnings: Neurogene Beats EPS for Q1 2024July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 10, 2024 | markets.businessinsider.comNeurogene Inc. Q1 Loss Beats EstimatesMay 10, 2024 | washingtonpost.comNeurogene: Q1 Earnings SnapshotMay 10, 2024 | businesswire.comNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesMay 7, 2024 | businesswire.comNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingMay 4, 2024 | markets.businessinsider.comOptimistic Buy Rating for Neurogene’s NGN-401 Anticipating RMAT Designation and Promising Clinical DataApril 30, 2024 | nasdaq.comLeerink Partners Initiates Coverage of Neurogene (NGNE) with Outperform RecommendationApril 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene’s Promising Rett Syndrome Gene Therapy, NGN-401April 22, 2024 | businesswire.comNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingMarch 26, 2024 | seekingalpha.comNeurogene Stock: Gene Therapy Specialist May Break Chain Of Failed MergersSee More Headlines Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CUSIPN/A CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year FoundedN/APrice Target and Rating Average Stock Price Target$51.33 High Stock Price Target$65.00 Low Stock Price Target$31.00 Potential Upside/Downside+18.5%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.04% Return on Assets-27.25% Debt Debt-to-Equity RatioN/A Current Ratio14.73 Quick Ratio14.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book2.98Miscellaneous Outstanding Shares12,980,000Free Float11,692,000Market Cap$562.16 million OptionableNo Data Beta1.45 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Rachel L. McMinn Ph.D. (Age 51)Founder, Executive Chair & CEO Comp: $676.54kMs. Christine Mikail Cvijic J.D. (Age 46)President, CFO & Corporate Secretary Comp: $623.29kDr. Stuart Cobb Ph.D. (Age 54)Chief Scientific Officer Comp: $478.81kMr. Arvind SreedharanSenior Vice President of Business OperationsMs. Donna M. Cochener-Metcalfe J.D. (Age 49)Senior VP & General Counsel Dr. Effie Albanis M.D.Senior Vice President of Early Clinical & Translational ResearchDr. Andrew E. Mulberg CPIFAAP, M.D., Senior Vice President of Regulatory Affairs, Quality Assurance & Quality ControlMr. Ricardo JimenezSenior Vice President of Technical OperationsDr. Julie Jordan M.D. (Age 52)Chief Medical Officer More ExecutivesKey CompetitorsDeciphera PharmaceuticalsNASDAQ:DCPHRocket PharmaceuticalsNASDAQ:RCKTProtagonist TherapeuticsNASDAQ:PTGXMaravai LifeSciencesNASDAQ:MRVIEdgewise TherapeuticsNASDAQ:EWTXView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 30,428 shares on 7/26/2024Ownership: 0.234%Redmile Group LLCSold 11,645 shares on 5/16/2024Ownership: 7.205%Janus Henderson Group PLCSold 28,335 shares on 5/16/2024Ownership: 6.266%Baker BROS. Advisors LPBought 2,499 shares on 5/15/2024Ownership: 3.513%Vanguard Group Inc.Bought 457,062 shares on 5/10/2024Ownership: 3.943%View All Institutional Transactions NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $19.38 at the start of the year. Since then, NGNE shares have increased by 131.3% and is now trading at $44.83. View the best growth stocks for 2024 here. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) announced its earnings results on Friday, May, 10th. The company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.03. Who are Neurogene's major shareholders? Neurogene's top institutional investors include Bank of New York Mellon Corp (0.23%). How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NGNE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGNE Stock Alerts